PCA3 and prostate carcinoma: The study by Rubio-Briones et al., analyzing 492 men with PSA 3–10 ng/mL, compared 2-gene urine-based molecular test targeting mRNAs with Prostate Cancer Antigen 3 (PCA3), European Randomized Screening in Prostate Cancer (ERSPC) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.